Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 456,099
  • Shares Outstanding, K 121,303
  • Annual Sales, $ 36,860 K
  • Annual Income, $ -171,670 K
  • 60-Month Beta 1.50
  • Price/Sales 12.47
  • Price/Cash Flow N/A
  • Price/Book 12.46
Trade MRSN with:

Options Overview Details

View History
  • Implied Volatility 170.56% ( -124.35%)
  • Historical Volatility 64.11%
  • IV Percentile 85%
  • IV Rank 22.08%
  • IV High 605.76% on 11/16/23
  • IV Low 47.27% on 11/09/23
  • Put/Call Vol Ratio 4.09
  • Today's Volume 56
  • Volume Avg (30-Day) 381
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 14,166
  • Open Int (30-Day) 9,309

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.21
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +65.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +3.53%
on 04/17/24
5.11 -31.12%
on 03/21/24
-1.52 (-30.16%)
since 03/15/24
3-Month
2.52 +39.96%
on 01/19/24
6.28 -43.95%
on 03/11/24
+0.63 (+21.80%)
since 01/17/24
52-Week
0.80 +339.23%
on 07/27/23
9.62 -63.41%
on 06/12/23
-0.86 (-19.63%)
since 04/17/23

Most Recent Stories

More News
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

DTC.CN : 1.5300 (-2.55%)
MGNX : 16.10 (-3.48%)
IOVA : 11.80 (-1.01%)
MRTX : 58.70 (-0.17%)
MRSN : 3.52 (-6.38%)
DTCFF : 1.0800 (+5.88%)
LLY : 750.77 (+0.54%)
PFE : 25.42 (-1.05%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)
MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) violated federal...

MRSN : 3.52 (-6.38%)
MRSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

/PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation...

MRSN : 3.52 (-6.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...

MRSN : 3.52 (-6.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 4.20
2nd Resistance Point 4.01
1st Resistance Point 3.77
Last Price 3.52
1st Support Level 3.34
2nd Support Level 3.15
3rd Support Level 2.91

See More

52-Week High 9.62
Fibonacci 61.8% 6.25
Fibonacci 50% 5.21
Fibonacci 38.2% 4.17
Last Price 3.52
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar